The Veet hair removal system for hairy gorillas is flying off the shelf.

This surely has to be a buy? DYOR

http://www.reckittbenckiser.com/

Prime Markets - RB. is a buy with target price £47

Up another quid today.

£45 quid this morning.

These are making new highs almost daily of late.

no wonder HG+HC index continues to spiral

Just £46.26 so far today!

here's the answer to today's slump .....

Consumer products group Reckitt Benckiser was the worst performer, slumping 182.5p at 4,333.5p on news the US FDA has given the go-ahead to rival drug manufacturers to produce a generic version of the company's Suboxone product in the US. In response, Investec downgraded its recommendation on the stock to sell from hold

==============

i would guess the drop is overdone as is the nature of these things, though when wall street opens today, there may be further selling ...... worth keeping an eye on HG+HC index, as a buying opportunity may be on the near horizon after this sharp correction - but be very aware that its volatility is scary

25 February - Deutsche bank - RB. still a buy and retains its price target of £48.
Investec did downgrade from hold to sell but retained its TP of £42.60.

Reuters take :-

Reckitt loses bid to change U.S. drug packaging rules

(Reuters) - The U.S. drugs regulator has rejected goods manufacturer Reckitt Benckiser's call for stricter packaging for its heroin addiction treatment, instead approving generic production for the drug.

The British company's pharmaceuticals division makes most of its profit from Suboxone, a treatment containing buprenorphine, for recovering heroin addicts.

Last year, Reckitt voluntarily withdrew the sale of Suboxone tablets in the U.S. in favor of an individually sealed film version, citing a higher risk of children mistakenly getting their hands on the tablets.

Credit Suisse Neutral 4,581.50 4,516.00 4,250.00 4,900.00 Reiterates

Bank of America Merrill Lynch retains buy and raises target to £52.50

INTERIM MANAGEMENT STATEMENT Q1 2013


Highlights: Q1 (at constant rates)

* Total net revenue growth of +7%. Ex. RBP growth +6%.

* LFL net revenue growth excluding RBP of +6%.

* Continued very strong growth in Emerging Market Areas. +3% LFL growth in
ENA.

* Strong underlying growth across Health & Hygiene boosted by higher
incidence of flu. Good performance from Mucinex, Strepsils, Nurofen, Durex,
Dettol / Lysol & Finish.

* Schiff integration progressing well; strong Q1 on both Schiff and Guilong
China.

* RBP - total US market volume film share 69%, early generic tablet impact as
expected.

Credit Suisse Neutral 4,700.00 4,900.00 4,650.00 Reiterates

Nomura Buy 4,700.00 4,900.00 4,800.00 Retains

Bank of America Merrill Lynch Buy 4,700.00 5,250.00 5,250.00 Retains

but sp shows why today's "clunk" on HG+HC index

Half-Year Results 2013

3rd Quarter Results

Highlights:

* Year to date like-for-like (LFL) net revenue growth (ex RBP) of +5%, driven
by Emerging Markets Areas (EM) growth and continued growth in ENA.
* Strong Q3 LFL growth of +5% (ex RBP) - ENA +2% LAPAC +10% and RUMEA +5%.
* Continued excellent Health & Hygiene performances, and a solid Home
performance in challenging market conditions.
* RBP - volume (mg) market share of Film maintained at around 68% since
launch of generic tablets and strategic review of RBP to commence.

Investec & Liberum both gave 'sell' ratings yesterday!

Investec after results today have upgraded their sell rating to hold

Canaccord Genuity Sell 4,729.50 4,500.00 4,100.00 4,100.00 Reiterates

Societe General retains hold but ups target price to £47.50
Deutsche Bank retains but and price target £51.